Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Before diving into the highlights '24, we did put on the 20 years Molecular Partners logo because it is our ... This number is clearly volatile by design. And this year, I think we, as I said ...

Before joining Alkermes, Dr. von Moltke was Vice President, Clinical and Exploratory Pharmacology at Sanofi/Genzyme ... word mark, logo mark, and the “lightning bolt” design are trademarks ...

Logos aren’t just there to look pretty or to label your brand; they should be designed purposefully, with meaning behind each ...

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €114.00. The company’s shares closed yesterday ...

Sanofi has shared a deeper dive into its 469 ... the partners had just “put the final touches” to the phase 3 design. The design is “really based on the modeling and simulation that we ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

Sanofi licensed the antibody from Alopexx Pharmaceuticals, a precursor to the current biotech of the same name, in 2009 but faced challenges such as the slow enrollment (PDF) of a phase 2a trial.

As one of the NHL's Original Six, the New York Rangers will always be one of the league's most storied franchises. So, with their 100th anniversary fast approa ...